Patients were randomly assigned ( 1:1:1 ) to receive either chemotherapy alone , chemotherapy with sequential GV1001 ( sequential chemoimmunotherapy ) , or chemotherapy with concurrent GV1001 ( concurrent chemoimmunotherapy ) .